{"paper_id":"90cbd10b-857c-4031-87b0-9992a160b3ca","body_text":"Abstract\nEndometriosis is a chronic estrogen-dependent gynecological disease characterized by the presence of endometrial tissue (stroma and/or glands) outside the uterine cavity, which induces a chronic, inflammatory reaction. Most commonly this involves ovaries and fallopian tubes, and rarely endometrial tissue may spread beyond pelvic organs.\nAccess this chapter\nTax calculation will be finalised at checkout\nPurchases are for personal use only\nSimilar content being viewed by others\nReferences\nViganò P, Parazzini F, Somigliana E, Vercellini P. Endometriosis: epidemiology and aetiological factors. Best Pract Res Clin Obstet Gynaecol. 2004;18:177–200.\nThe Practice Committee of the American Society for Reproductive Medicine. Endometriosis and infertility. Fertil Steril. 2006;86(Suppl 4):S15660.\nKoga K, Takamura M, Fujii T, Osuga Y. Prevention of the recurrence of symptom and lesions after conservative surgery for endometriosis. Fertil Steril. 2015;104:793–801.\nCrosignani PG, Olive D, Bergqvist A, Luciano A. Advances in the management of endometriosis: an update for clinicians. Hum Reprod Update. 2006;12:179–89.\nDunselman GAJ, Vermeulen N, Becker C, et al. ESHRE guideline: management of women with endometriosis. Hum Reprod. 2014;29:400–12. https://doi.org/10.1093/humrep/det457.\nFerrero S, Abbamonte LH, Giordano M, et al. Deep dyspareunia and sex life after laparoscopic excision of endometriosis. Hum Reprod. 2007;22:1142–8.\nVercellini P, De Giorgi O, Mosconi P, et al. Cyproterone acetate versus a continuous monophasic oral contraceptive in the treatment of recurrent pelvic pain after conservative surgery for symptomatic endometriosis. Fertil Steril. 2002;77:52–61.\nMuneyyirci-Delale O, Anopa J, Charles C, Mathur D, Parris R, Cutler JB, Salame G, Abulafi O. Medical management of recurrent endometrioma with long-term norethindrone acetate. Int J Women’s Health. 2012;4:149–54.\nKohler G, Faustmann TA, Gerlinger C, Seitz C, Mueck AO. A dose-ranging study to determine the efficacy and safety of 1, 2, and 4 mg of dienogest daily for endometriosis. Int J Gynaecol Obstet. 2010;108(1):21–5.\nHarada T, Momoeda M, Taketani Y, et al. Dienogest is as effective as intranasal buserelin acetate for the relief of pain symptoms associated with endometriosis–a randomized, doubleblind, multicenter, controlled trial. Fertil Steril. 2009;91(3):675–81.\nDel Forno S, Mabrouk M, Arena A, Mattioli G, Giaquinto I, Paradisi R, Seracchioli R. Dienogest or norethindrone acetate for the treatment of ovarian endometriomas: can we avoid surgery? Eur J Obstet Gynecol Reprod Biol. 2019;238:120–4.\nFedele L, Bianchi S, Zanconato G, et al. Use of a levonorgestrel-releasing intrauterine device in the treatment of rectovaginal endometriosis. Fertil Steril. 2001;75:485–8.\nBlumenthal PD, Gemzell-Danielsson K, Marintcheva-Petrova M. Tolerability and clinical safety of Implanon®. Eur J Contracept Reprod Health Care. 2008;13:29.\nCroxatto HB, Mäkäräinen L. The pharmacodynamics and efficacy of Implanon. An overview of the data. Contraception. 1998;58(6 Suppl):91S97S.\nDi Carlo C, Sansone A, De Rosa N, Gargano V, Tommaselli GA, Nappi C, Bifulco G. Impact of an implantable steroid contraceptive (Etonogestrel-releasing implant) on quality of life and sexual function: a preliminary study. Gynecol Endocrinol. 2014;30(1):53–6.\nPonpuckdee J, Taneepanichskul S. The effects of implanon in the symptomatic treatment of endometriosis. J Med Assoc Thail. 2005;88(Suppl 2):S7–10, 56\nFerrero S, Scala C, Ciccarelli S, Vellone VG, Barra F. Treatment of rectovaginal endometriosis with the etonogestrel-releasing contraceptive implant. Gynecol Endocrinol. 2019;12:1–5.\nYisa SB, Okenwa AA, Husemeyer RP. Treatment of pelvic endometriosis with etonogestrel subdermal implant (Implanon). J Fam Plann Reprod Health Care. 2005;31:67–70.\nWalch K, Unfried G, Huber J, et al. Implanon® versus medroxyprogesterone acetate: effects on pain scores in patients with symptomatic endometriosis—a pilot study. Contraception. 2009;79:29–34.\nSansone A, De Rosa N, Giampaolino P, Guida M, Laganà AS, Di Carlo C. Effects of etonogestrel implant on quality of life, sexual function, and pelvic pain in women suffering from endometriosis: results from a multicenter, prospective, observational study. Arch Gynecol Obstet. 2018;298(4):731–6.\nCarvalho N, Margatho D, Cursino K, Benetti-Pinto CL, Bahamondes L. Control of endometriosis-associated pain with etonogestrel-releasing contraceptive implant and 52-mg levonorgestrel-releasing intrauterine system: randomized clinical trial. Fertil Steril. 2018;110(6):1129–36.\nMargatho D, Mota Carvalho N, Eloy L, Bahamondes L. Assessment of biomarkers in women with endometriosis-associated pain using the ENG contraceptive implant or the 52 mg LNG-IUS: a non-inferiority randomised clinical trial. Eur J Contracept Reprod Health Care. 2018;23(5):344–50.\nMargatho D, Carvalho NM, Bahamondes L. Endometriosis-associated pain scores and biomarkers in users of the etonogestrel-releasing subdermal implant or the 52-mg levonorgestrel-releasing intrauterine system for up to 24 months. Eur J Contracept Reprod Health Care. 2020;18:1–8.\nMansour D, Korver T, Marintcheva-Petrova M, Fraser IS. The effects of Implanon on menstrual bleeding patterns. Eur J Contracetp Reprod Health Care. 2008;13(Suppl 1):13–28.\nGuida M, Visconti F, Cibarelli F, Granozio G, Troisi J, Martini E, Nappi R. Counseling and management of patients requesting subcutaneous contraceptive implants: proposal for a decisional algorithm. Gynecol Endocrinol. 2014;30(7):525–31.\nDi Carlo C, Guida M, De Rosa N, Sansone A, Gargano V, Cagnacci A, Nappi C. Bleeding profile in users of an etonogestrel subdermal implant: effects of anthropometric variables. An observational uncontrolled preliminary study in Italian population. Gynecol Endocrinol. 2015;31(6):491–4.\nAuthor information\nAuthors and Affiliations\nCorresponding author\nEditor information\nEditors and Affiliations\nRights and permissions\nCopyright information\n© 2021 International Society of Gynecological Endocrinology\nAbout this chapter\nCite this chapter\nVisconti, F., Di Carlo, C. (2021). The Etonogestrel Contraceptive Implant as a Therapy for Endometriosis. In: Genazzani, A.R., Nisolle, M., Petraglia, F., Taylor, R.N. (eds) Endometriosis Pathogenesis, Clinical Impact and Management. ISGE Series. Springer, Cham. https://doi.org/10.1007/978-3-030-57866-4_7\nDownload citation\nDOI: https://doi.org/10.1007/978-3-030-57866-4_7\nPublished:\nPublisher Name: Springer, Cham\nPrint ISBN: 978-3-030-57865-7\nOnline ISBN: 978-3-030-57866-4\neBook Packages: MedicineMedicine (R0)","source_license":"CC0","license_restricted":false}